Ultragenyx Pharmaceutical
RARE
221 hedge funds and large institutions have $6.01B invested in Ultragenyx Pharmaceutical in 2021 Q3 according to their latest regulatory filings, with 25 funds opening new positions, 85 increasing their positions, 79 reducing their positions, and 43 closing their positions.
1.23% more ownership
Funds ownership: 97.04% → 98.28% (+1.2%)
8% more repeat investments, than reductions
Existing positions increased: 85 | Existing positions reduced: 79
4% less capital invested
Capital invested by funds: $6.24B → $6.01B (-$228M)
8% less funds holding
Funds holding: 241 → 221 (-20)
27% less call options, than puts
Call options by funds: $3.59M | Put options by funds: $4.9M
42% less first-time investments, than exits
New positions opened: 25 | Existing positions closed: 43
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$191M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$41.6M |
| 3 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$41.1M |
| 4 |
Alkeon Capital Management
New York
|
+$35.7M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
+$32.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital Research Global Investors
Los Angeles,
California
|
-$109M |
| 2 |
Millennium Management
New York
|
-$41.2M |
| 3 |
Renaissance Technologies
New York
|
-$35.3M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$33.7M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$33.2M |
RARE Hedge Fund Activity: Q3 2021 in Review
221 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Ultragenyx Pharmaceutical (RARE) for Q3 2021, worth a combined $6.01B — down 3.6% from $6.24B a quarter earlier.
Sellers outnumbered buyers: 43 funds closed out of RARE and 25 opened new positions — a net loss of 18 holders — while 79 trimmed existing stakes and 85 added.
The largest buyer was Wellington Management Group, adding an estimated $191M. The largest seller was Capital Research Global Investors, cutting an estimated $109M.
- 221 institutional investors held Ultragenyx Pharmaceutical (RARE) as of Q3 2021, down from 241 in Q2 2021.
- Funds reported $6.01B of Ultragenyx Pharmaceutical stock for Q3 2021, down 3.6% quarter-over-quarter.
- 25 funds opened new Ultragenyx Pharmaceutical positions in Q3 2021 and 43 closed out, a net change of -18 holders.
- The largest Ultragenyx Pharmaceutical buyer in Q3 2021 was Wellington Management Group, an estimated $191M added.
- The largest Ultragenyx Pharmaceutical seller in Q3 2021 was Capital Research Global Investors, an estimated $109M sold.
Based on aggregated 13F filings for Q3 2021.